Celastrol, a natural bioactive ingredient derived from Tripterygium wilfordii Hook F, exhibits
significant broad-spectrum anticancer activities for the treatment of a variety of cancers …

Cancer is one of the world's biggest healthcare burdens and despite the current
advancements made in treatment plans, the outcomes for oncology patients have yet to …

Celastrol (CEL), an active compound isolated from the root of Tripterygium wilfordii, exhibits
broad anticancer activities. However, its poor stability, narrow therapeutic window and …

Rheumatoid arthritis (RA) is a systemic inflammatory disorder which can cause bone and
cartilage damage leading to disability, yet the treatment remains unsatisfactory nowadays …

Several efforts have been extensively accomplished for the amelioration of the cancer
treatments using different types of new drugs and less invasives therapies in comparison …

Ocular delivery is the most challenging aspect in the field of pharmaceutical research. The
major hurdle for the controlled delivery of drugs to the eye includes the physiological static …

Corneal stromal fibrosis is a common cause of visual impairment resulting from corneal
injury, inflammation and surgery. Therefore, there is an unmet need for inhibiting corneal …

Background Cancer is the world's leading cause of death and a key hindrance to extending
life expectancy. Celastrol, a bioactive compound derived from Tripterygium wilfordii, has …

In 1971, Folkman proposed that tumors could be limited to very small sizes by blocking
angiogenesis. Angiogenesis is the generation of new blood vessels from pre-existing …

Celastrol, a quinone‐methide triterpenoid, was extracted from Tripterygium wilfordii Hook. F.
in 1936 for the first time. Almost 70 years later, it is considered one of the molecules most …